Westerink J, Matthiessen KS, Nuhoho S, Fainberg U, et al. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care 2022 Mar 9. pii: 144726. doi: 10.2337/dc21-1138.
PMID: 35263432